An observational study in T-LGL Leukemia and NK-LGL Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational
Among 10 studies in Leukemia, Large Granular Lymphocytic with a site in China — 9 open to participants now, 9 under way, 1 of them phase 3. Leukemia, Large Granular Lymphocytic · China.
Among the 10 studies in Leukemia, Large Granular Lymphocytic with a site in China, this one is the only one that started in 2000, is one of 3 observational ones, and was the 8th registered.
144 studies on the registry are indexed under Leukemia, Large Granular Lymphocytic; 19 are open to participants now.
Browse Leukemia, Large Granular Lymphocytic studies →9 of the 10 studies in Leukemia, Large Granular Lymphocytic with a site in China are open now. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Rong Tao · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Leukemia, Large Granular Lymphocytic studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 1
First in 2000; this study’s year is marked. 1 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9,999 is above the median of 1,250 across 18 observational studies indexed under Leukemia, Large Granular Lymphocytic.
Median enrollment 42 across the 7 interventional studies, 2,300 across the 3 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 4 most frequent:
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 412 studies on the registry; 291 are open to participants now.
Institute of Hematology & Blood Diseases Hospital, China has 7 studies filed under Leukemia, Large Granular Lymphocytic — fewer than ten, so there is no comparison to draw.
1 of the studies in Leukemia, Large Granular Lymphocytic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06716658Institute of Hematology & Blood Diseases Hospital, ChinaJAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | 2026-11-15 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Leukemia, Large Granular Lymphocytic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology.
The objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (LGLL) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in China.
Pantients diagnosed as LGLL.
Diagnostic criteria for LGLL (Large Granular Lymphocytic Leukemia):
Increased number of circulating LGL cells (>0.5×10\^9/L) identified based on complete blood count and/or a consistent immunophenotypic pattern; Evidence of clonality confirmed by flow cytometry and/or molecular biology techniques; In patients with a low LGL cell count, diagnosis can still be made if there is a characteristic immunophenotype, STAT3 mutation, or bone marrow pathology abnormalities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who were diagnosed with LGLL in the investigating hospitals from Jan 1, 2000.
Other: A combined retrospective and prospective observational follow-up
The NICHE-LGLL will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
Hematologic response
Hematologic response contains improvements in neutrophil count, hemoglobin level, and platelet count
Time frame: Assessments will be conducted at baseline, 6 months, 12 months, and 24 months after treatment, as well as at study completion, with an average interval of approximately 1 year.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2000 (actual). Primary completion is estimated for Dec 2070, 851 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Large Granular Lymphocytic →
Institute of Hematology & Blood Diseases Hospital, China →